These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15879792)

  • 1. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    Walsh PC
    J Urol; 2005 Jun; 173(6):1966. PubMed ID: 15879792
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
    Oh WK; Kantoff PW; Weinberg V; Jones G; Rini BI; Derynck MK; Bok R; Smith MR; Bubley GJ; Rosen RT; DiPaola RS; Small EJ
    J Clin Oncol; 2004 Sep; 22(18):3705-12. PubMed ID: 15289492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 4. [PSA progression under hormone therapy - of prognostic relevance?].
    Miller K
    Aktuelle Urol; 2012 Jul; 43(4):262-4. PubMed ID: 22869497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer.
    Meyer JP; Gillatt DA
    Prostate Cancer Prostatic Dis; 2002; 5(1):13-5. PubMed ID: 15195124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical and biological study of androgen independent prostate cancer (AI PCa).
    Logothetis CJ; Hoosein NM; Hsieh JT
    Semin Oncol; 1994 Oct; 21(5):620-9. PubMed ID: 7524155
    [No Abstract]   [Full Text] [Related]  

  • 8. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
    Kobayashi M; Kuramoto H; Ota J; Fujimoto N
    Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intermittent hormonal treatment in prostatic cancer].
    Zerbib M; Conquy S
    Prog Urol; 1997 Dec; 7(6):1026-7. PubMed ID: 9490134
    [No Abstract]   [Full Text] [Related]  

  • 13. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    Loblaw DA; Mendelson DS; Talcott JA; Virgo KS; Somerfield MR; Ben-Josef E; Middleton R; Porterfield H; Sharp SA; Smith TJ; Taplin ME; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
    J Clin Oncol; 2004 Jul; 22(14):2927-41. PubMed ID: 15184404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
    Ward JF
    Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
    [No Abstract]   [Full Text] [Related]  

  • 19. PC-SPES: hope or hype?
    Kosty MP
    J Clin Oncol; 2004 Sep; 22(18):3657-9. PubMed ID: 15289490
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.